Downregulation of CUEDC2 prevents doxorubicin‑induced cardiotoxicity in H9c2 cells

Molecular Medicine Reports
Xianpu ZhangWei Cheng

Abstract

Treatment with doxorubicin (DOX), which is an effective anticancer agent, is limited by cardiotoxicity. CUE domain‑containing 2 (CUEDC2) serves a role in numerous cellular processes. The present study aimed to elucidate the potential function of CUEDC2 in DOX‑induced cardiotoxicity. Cell Counting kit‑8 assay demonstrated that DOX induced cytotoxicity of H9c2 cells in a dose‑dependent manner. Flow cytometry demonstrated that downregulation of CUEDC2 reduced the levels of DOX‑induced reactive oxygen species. Furthermore, compared with in the DOX‑treated group, the activity of superoxide dismutase was increased in the DOX + small interfering RNA (si)CUEDC2 group; whereas, the malondialdehyde content was reduced in the DOX + siCUEDC2 group. In addition, flow cytometric analysis indicated that mitochondrial membrane potential was maintained following the depletion of CUEDC2. Furthermore, CUEDC2 downregulation significantly inhibited DOX‑induced apoptosis. The expression levels of proapoptotic genes, including B‑cell lymphoma 2 (Bcl‑2)‑associated X protein, cleaved caspase‑3 and cytochrome c were inhibited by the depletion of CUEDC2. Conversely, the expression levels of the anti‑apoptotic gene Bcl‑2 were elevated in the CUEDC2 knockd...Continue Reading

References

Mar 15, 1976·Experimental Cell Research·B W Kimes, B L Brandt
Jul 16, 1981·The New England Journal of Medicine·R C YoungC E Myers
May 1, 1995·Postgraduate Medical Journal·L Samuel
Aug 3, 1993·Biochemical Pharmacology·A Skladanowski, J Konopa
Jan 23, 2002·Cell Death and Differentiation·Guy S Salvesen
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
May 27, 2003·Apoptosis : an International Journal on Programmed Cell Death·J D LyA Lawen
Oct 7, 2003·The Journal of Biological Chemistry·Andrew SuntersEric W-F Lam
Oct 21, 2006·Biochemical Society Transactions·E W-F LamM Petkovic
Feb 20, 2007·Current Biology : CB·Matthew E Carter, Anne Brunet
Jan 8, 2008·The Journal of Biological Chemistry·Dayong ZhaiJohn C Reed
Mar 25, 2009·Neoplasia : an International Journal for Oncology Research·Yang YangWei-Guo Zhu
Jun 10, 2009·Journal of Medical Genetics·S GhavamiM Los
Mar 31, 2010·The Journal of Cell Biology·Caoimhín G ConcannonJochen H M Prehn
Nov 5, 2010·Pharmacogenetics and Genomics·Caroline F ThornRuss B Altman
Nov 18, 2010·In Vitro Cellular & Developmental Biology. Animal·Sarah J WatkinsHelen M Arthur
Oct 7, 2011·Protein & Cell·Jianghong Man, Xuemin Zhang
Feb 1, 2012·Archives of Medical Science : AMS·Ayodele MorakinyoOlufeyisipe Adegoke
Aug 8, 2012·Clinical Chemistry and Laboratory Medicine : CCLM·Mari Carmen Gomez-CabreraJose Viña
May 23, 2015·Journal of Cancer·Aichun WangAijun Liu
Jun 12, 2016·EMBO Molecular Medicine·Zhao JianAi-Ling Li

❮ Previous
Next ❯

Methods Mentioned

BETA
ubiquitination
transfection
flow cytometry
Assay
MDA

Software Mentioned

Quantity One
Accuri CFlow Plus
GraphPad
GraphPad Prism

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.